8-K: TuHURA Biosciences Secures Exclusive Rights to Kineta's Anti-VISTA Antibody in Potential Acquisition

TuHURA Biosciences has entered into an agreement with Kineta for exclusive rights to acquire Kineta's KVA12123 anti-VISTA antibody, a novel checkpoint inhibitor, while also securing a $5 million private investment.

Summary

• TuHURA Biosciences has signed an Exclusivity and Right of First Offer Agreement with Kineta for the potential acquisition of Kineta's KVA12123 anti-VISTA antibody.
• The agreement grants TuHURA exclusive rights to acquire Kinetas worldwide patents, patent rights, and other assets related to KVA12123.
• The exclusivity period runs from July 3, 2024, to October 1, 2024, with a potential extension of up to 20 days.
• TuHURA will pay Kineta $5.0 million, with $2.5 million paid at signing and an additional $2.5 million due by July 15, 2024.
• An additional $150,000 may be paid for each of the two potential 10-day renewal periods, up to a total of $300,000.
• TuHURA also completed a $5.0 million private placement with an existing shareholder.
• The shareholder is entitled to a 1.5% royalty on certain sales of the product.
• KVA12123 is a VISTA blocking immunotherapy that has shown a favorable safety profile in clinical trials.
• The antibody is designed to reverse VISTA immune suppression and remodel the tumor microenvironment.
• KVA12123 has demonstrated strong monotherapy tumor growth inhibition in preclinical models without evidence of cytokine release syndrome.
• TuHURA is also in the process of merging with Kintara Therapeutics, with the combined company expected to operate under the name TuHURA Biosciences, Inc. and trade on Nasdaq under the ticker HURA.

Sentiment

Score: 8

Explanation: The document conveys a positive outlook with the potential acquisition of a promising asset and a concurrent private placement. The merger plans also contribute to a positive sentiment, although risks associated with the merger and clinical trials are acknowledged.

Positives

• TuHURA gains access to a promising novel checkpoint inhibitor, KVA12123, which has shown a favorable safety profile.
• KVA12123 has demonstrated strong monotherapy tumor growth inhibition in preclinical models.
• The acquisition aligns with TuHURA's focus on overcoming resistance to cancer immunotherapy.
• The $5 million private placement strengthens TuHURA's balance sheet.
• The merger with Kintara will create a combined company with a diversified oncology pipeline.
• KVA12123 targets a different mechanism of action than other checkpoint inhibitors, potentially addressing a broader range of cancers.

Negatives

• The acquisition of KVA12123 is not yet finalized and is subject to a definitive agreement.
• The exclusivity period is limited, and there is no guarantee that a final acquisition agreement will be reached.
• TuHURA is paying $5 million for the exclusivity rights, which may not result in a successful acquisition.
• The 1.5% royalty to the investor could impact future profitability.

Risks

• The proposed merger between Kintara and TuHURA is subject to customary closing conditions, including stockholder approval.
• There is a risk that the merger may not be completed or may be delayed.
• The success of KVA12123 is not guaranteed, and further clinical trials are needed.
• The combined company may face challenges in integrating the operations of Kintara and TuHURA.
• There is a risk that the combined company may not be able to achieve its financial goals.
• The company is subject to risks related to clinical trials, regulatory approvals, and market competition.

Future Outlook

The combined company is expected to focus on advancing TuHURA's personalized cancer vaccine(s) and bi-functional ADCs, and the acquisition of KVA12123 could further enhance their pipeline. The merger is expected to close in the third quarter of 2024.

Management Comments

• Dr. James Bianco, Chief Executive Officer of TuHURA, stated that KVA12123 has multiple synergies with their existing technologies and could be a promising addition to their pipeline.
• Craig W. Philips, President of Kineta, believes TuHURA is well-positioned to advance KVA12123 and will be an excellent partner for the program.

Industry Context

This announcement reflects the ongoing interest in novel checkpoint inhibitors and the growing focus on overcoming resistance to existing immunotherapies. The acquisition of KVA12123 could position TuHURA as a key player in the immuno-oncology space, particularly in addressing tumors that do not respond to current treatments.

Comparison to Industry Standards

• The development of VISTA inhibitors is a relatively new area in immuno-oncology, with few competitors having advanced clinical programs.
• KVA12123's favorable safety profile, with no evidence of CRS, differentiates it from some other VISTA-targeting therapies that have shown toxicity issues.
• The combination of KVA12123 with Merck's KEYTRUDA is a common strategy in the industry, aiming to enhance the efficacy of checkpoint inhibitors.
• TuHURA's focus on personalized cancer vaccines and bi-functional ADCs aligns with the industry trend towards more targeted and effective cancer treatments.
• The merger between Kintara and TuHURA is a strategic move to combine resources and expertise, similar to other consolidations in the biotech sector.

Stakeholder Impact

• Shareholders of Kintara and TuHURA will be impacted by the proposed merger and the potential acquisition of KVA12123.
• Employees of both companies may experience changes due to the merger.
• Patients may benefit from the development of new cancer therapies.
• The private placement investor will receive a royalty on certain sales of the product.

Next Steps

• TuHURA and Kineta will continue discussions to potentially reach a definitive agreement for the acquisition of KVA12123.
• TuHURA will continue to advance its IFx-2.0 Phase 3 trial and bi-functional ADCs.
• Kintara and TuHURA will seek stockholder approval for the proposed merger.
• The merger is expected to close in the third quarter of 2024.

Key Dates

Keywords

KVA12123, VISTA, immunotherapy, checkpoint inhibitor, TuHURA Biosciences, Kineta, acquisition, merger, oncology, cancer, clinical trials